Enanta Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Enanta Pharmaceuticals

07/08/2023 23:02

* Enanta Pharmaceuticals Inc  ENTA.OQ  reported a quarterly
adjusted loss of $1.86​​ per share for the quarter ended in
June. The mean expectation of eight analysts for the quarter was
for a loss of $2.33 per share.
    * Revenue fell 3% to $18.89 million from a year ago;
analysts
expected $18.06 million. 
    * Enanta Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.86​.
    * The mean earnings estimate of analysts had risen by
about 2.6%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Enanta Pharmaceuticals Inc shares had fallen by 7.4% this
quarter and lost 57.4% so far this year.
    * The company reported a quarterly loss of $39.07 million.
    * Wall Street's median 12-month price target for Enanta
Pharmaceuticals Inc is $37.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 7 at 10:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -2.33          -1.86          Beat
 Mar. 31 2023      -1.98          -1.79          Beat
 Dec. 31 2022      -1.59          -1.39          Beat
 Sep. 30 2022      -1.35          -1.27          Beat